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Abstract
Aims—Given the high prevalence of psychotropic medication use in people with dementia and
the potential for different prescribing practices in men and women, our study aimed to investigate
sex differences in psychotropic medication use in older adults with Alzheimer's disease (AD)
living in the US and Finland.
Methods—We used data collected between 2005 and 2011 as part of the National Alzheimer's
Coordinating Center (NACC) in the US, and Medication use and Alzheimer's disease (MEDALZ)
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cohorts in Finland. We evaluated psychotropic medication use (antidepressant, antipsychotic,
anxiolytic, sedative, or hypnotic) in participants aged 65 years or older. We employed
multivariable logistic regression adjusted for demographics, co-morbidities, and other medications
to estimate the magnitude of the association (adjusted odds ratio [aOR] with 95% confidence
intervals [CIs]) according to sex.

Author Manuscript

Results—We included 1099 NACC participants (502 [45.68%] men, 597 [54.32%] women), and
67,049 participants from the MEDALZ cohort (22,961 [34.24%] men, 44,088 [65.75%] women).
Women were more likely than men to use psychotropic medications: US, 46.2% vs. 33.1%, p <
0.001; Finland, 45.3% vs. 36.1%, p < 0.001; aOR was 2.06 (95% CI 1.58–2.70) in the US cohort
and 1.38 (95% CI 1.33–1.43) in the Finnish cohort. Similarly, of the different psychotropic
medications, women were more likely to use antidepressants (aOR-US: 2.16 [1.44–3.25], Finland:
1.52 [1.45–1.58]) and anxiolytics (aOR-US: 2.16 [1.83–3.96], Finland: 1.17 [1.13-1.23]) than
men.
Conclusionl—Older women with AD are more likely to use psychotropic medications than older
men, regardless of study population and country. Approaches to mitigate psychotropic medication
use need to consider different prescribing habits observed in older women vs. men with AD.

1 Introduction

Author Manuscript

Current evidence suggests a high prevalence of psychotropic medication use among people
with dementia. In a study of older people with dementia in the US, 57% used one or more
psychotropic medications consistently over a 1-year period, regardless of whether they were
living in the community or nursing homes (NH) [1]. Other studies have reported a similar
prevalence, with 51% of community-dwelling older people with Alzheimer's disease (AD) in
Finland being exposed to anticholinergic and sedative medications (mostly psychotropic
medications) [2]. Alarmingly, psychotropic polypharmacy is highly prevalent in older people
with dementia, with a recent study reporting an increase from 42% in 2004 to 50% in 2013
in patients being dispensed two or more psychotropic medications [3]. The observed high
prevalence of psychotropic medications is of concern given the potential for significant harm
and the limited evidence on efficacy in older people with dementia [4, 5]. Data from metaanalyses suggest that antipsychotic use in older people with dementia is associated with
greater mortality [6], and evidence from well-designed observational studies suggests an
association with a range of dose-dependent adverse events, including impaired physical
function, frailty, increased risk of hospitalization, and mortality [2, 7, 8].

Author Manuscript

Factors contributing to psychotropic medication use and subsequent poor clinical outcomes
in older people with dementia are complex. In particular, there are limited data on the role of
biological sex in determining psychotropic medication utilization patterns in older people
with cognitive impairment. However, sex is an important factor to consider in clinical
practice as it can influence healthcare, the choice of pharmacological treatments, and patient
outcomes [9, 10]. Disability and morbidity are more prevalent in older women than men;
therefore, this may explain why older women are more likely to use more medications
overall [11]. For instance, one study found that potentially inappropriate medication use was
more common in women (24.6%) than in men (19.3%) [12]. Moreover, older women were at
50% higher odds of receiving three or more psychotropic medications than men (adjusted
Drugs Aging. Author manuscript; available in PMC 2018 January 01.
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odds ratio 1.50; 95% confidence interval [CI] 1.47–1.53). Current evidence suggests that
women with dementia are more likely to use certain psychotropic medications such as
antipsychotics than men [13]. There are also differences in behavioral and psychological
symptoms of dementia with men being more physically aggressive, apathetic, and
regressive, while women tend to display depression, anxiety, and agitation more frequently
[14, 15]. This may result in sex differences in medication utilization patterns, with men
being more likely to use antipsychotics or a high dose [16]. Older men with dementia are
more likely to experience adverse events when given antipsychotics than older women [15,
17].

Author Manuscript

To date, no study has explicitly compared the role of sex on psychotropic prescribing
practices in older people with AD living in different countries. Our focus on comparing sex
differences in psychotropic medication prescribing between countries was driven by the
need to document patterns across populations with different healthcare systems, and
potentially identifying country-specific factors for psychotropic medication use that could
help guide targeted intervention to optimize medication use in this population [18].
Therefore, the aim of this study was to evaluate sex differences in psychotropic medication
prescribing (referred to as ‘use’ or ‘utilization’ hereafter) in older adults with AD living in
the US and Finland. We also aimed to examine sociodemographic and clinical
characteristics that contribute to these differences.

2 Methods
2.1 Study Design and Population

Author Manuscript

Our investigation was conducted using data from two cohorts: the National Alzheimer's
Coordinating Center (NACC) in the US and the Medication use and Alzheimer's disease
(MEDALZ) in Finland. Cohort data use was approved by local ethics committees at each
institution and owing to the de-identified nature of the data included in our current study,
informed consent was waived. Specifically, for the US data, the Alzheimer's Disease
Research Center Clinical/Research Core protocol was approved by the Institutional Review
Board of the University of Kentucky. Ethics committee approval was not required for the
MEDALZ cohort according to Finnish legislation as only register-based data were used and
persons were not contacted.
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2.1.1 US Cohort—The NACC was established in 1999 through the funding of Alzheimer's
Disease Centers (ADC) by the National Institute on Aging. Since inception of the Uniform
Data Set in 2005, 34 past and present ADC throughout the US collected self-reported
information and conducted standardized cognitive and behavioral assessments in participants
with the full range of cognitive functioning, from normal to dementia. Participants are
recruited through clinician or self-referral (patients or family members), or through active
community recruitment strategies following ADC-specific recruitment protocols. Detailed
descriptions of the cohort as well as the various instruments and assessments used for data
collection are described elsewhere [19–22]. Briefly, NACC UDS data includes information
on sociodemographic characteristics, family history, medical history, and medication use. In
addition, participants undergo neuropsychological evaluations using validated instruments.

Drugs Aging. Author manuscript; available in PMC 2018 January 01.
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For this investigation, we used UDS enrollment and yearly follow-up visits data collected
between 2005 and 2011 to reflect the similar time window available from the Finnish cohort.
We identified 1169 participants newly diagnosed with AD during the cohort follow-up (i.e.,
free of dementia at enrollment), of which 1099 were aged ≥65 years. A participant was
considered to have AD if they met the criteria for dementia and had probable AD as the
primary clinical diagnosis based on the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders
Association (NINCDS/ADRDA) criteria [23]. Subjects without dementia diagnosis or those
with non-AD dementia were excluded from this analysis.

Author Manuscript

2.1.2 Finnish Cohort—The MEDALZ cohort is a population-based register of all
community-dwelling individuals diagnosed with AD between 2005 and 2011 in Finland.
The MEDALZ cohort collected information from several nationwide registers including the
Prescription Register (1995–2012), Special Reimbursement Register (1972–2012), Hospital
Discharge Register (1972–2012), and Statistics Finland (socioeconomic data since 1970 and
causes of death 2005–12). The Prescription Register includes information on reimbursed
purchases of medications classified according to the Anatomical Therapeutic Chemical
classification system [24]. The register includes data on community-dwelling individuals
(i.e., medications used in hospital or NH are not recorded). Older adults with AD have been
identified from the Special Reimbursement Register [16, 25–28].

Author Manuscript

From this Finnish cohort, of the 70,718 adults diagnosed with AD between 2005 and 2011,
our study included 67,049 individuals aged ≥65 years who were alive at the time when
medication utilization was assessed (i.e., 6 months after the diagnosis). Similarly to the US
cohort, the AD diagnosis was based on the NINCDS/ADRDA and Diagnostic and Statistical
Manual of Mental Disorders, 4th edition criteria [23, 29]. In Finland, current guidelines for
care recommend that all persons with clinically verified AD should be prescribed antidementia drugs unless there are contraindications for use [30].
2.2 Study Variables

Author Manuscript

The index date was defined as the first visit when the patient was identified with AD during
the cohort follow-up (US cohort) or 6 months after the date of diagnosis (Finnish cohort).
Medication exposure in the US cohort was measured from self-reported data using the
‘brown bag’ medication review approach (i.e., the participant or a family member were
asked to bring all the medications to the research assessment) on prescription and over-thecounter medications for the 2-week window preceding the index date [21]. Medication
exposure in the MEDALZ data was defined as medications used during a 2-week period
before the index date from register-based data. The use periods were modeled with the
PRE2DUP method as previously described [31–33]. Exposure to psychotropic medication
was defined as the use of an antidepressant, antipsychotic, or an anxiolytic, sedative, or
hypnotic. We also assessed the use of medications approved for AD treatment and the total
number of medications used at the index date for each person in the two cohorts.

Sociodemographic characteristics included race, education, living situation, and type of
residence for the US cohort and socioeconomic position for the Finnish cohort. Race was

Drugs Aging. Author manuscript; available in PMC 2018 January 01.
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categorized as White, Black, or other. Education was categorized as high-school degree or
less, college education, or graduate education. Living situation was defined as living alone,
living with spouse or partner, or other living arrangements. Residence type was described as
single family residence, retirement community, assisted living (assisted living, boarding
home, adult family home, and skilled nursing facility, or NH), or other. Occupational
socioeconomic position was defined for those included in the Finnish cohort as the highest
recorded position since 1972 and was obtained from the censuses maintained by Statistics
Finland. A six-category variable was constructed with the following categories “managerial/
professional”, “office worker”, “farming/forestry”, “sales/industry/cleaning”, “unknown”,
and “did not respond” [34, 35].

Author Manuscript

Cognitive evaluation information was available only from the US data and included the
clinical dementia rating (CDR) [36], and the Mini-Mental State Examination (MMSE) [37].
In our study, we included the standard global CDR score categorized as no impairment
(CDR = 0), questionable impairment (CDR = 0.5), mild impairment (CDR = 1), and
moderate tosevere impairment (CDR = 2 or 3). MMSE score was categorized as normal
(MMSE = 27–30), mild impairment (MMSE = 21–26), moderate impairment (MMSE = 11–
20),or severe impairment (MMSE = 0–10).
Behavioral symptoms available only from the US data included information collected as part
of the Neuropsychiatric Inventory Questionnaire [38, 39]; specifically, for our study, the
analyses included indicators for the presence of symptoms of delusions, hallucinations,
agitation or aggression, depression or dysphoria, and anxiety.

Author Manuscript

Co-morbidities were measured at the index date for both cohorts. For the US cohort,
indicators were created based on the health history at the index date visit. For the Finnish
cohort, the Special Reimbursement Register data were used for defining co-morbidities.
Some co-morbidities were available for both cohorts (cardiovascular diseases, diabetes
mellitus, stroke, history of seizures [US cohort] or epilepsy [Finnish cohort]), but some of
them were only available for the US cohort (obesity, depression in the previous 2 years and
Geriatric Depression Scale [40], psychiatric diagnosis, urinary incontinence) or for the
Finnish cohort (history of hospital-treated depression, rheumatoid arthritis, asthma/chronic
obstructive pulmonary disease, history of hip fracture). Cardiovascular diseases indicators
included chronic heart failure, arterial hypertension, coronary artery disease, and chronic
arrhythmia. History of stroke and hip fracture were collected from the Hospital Discharge
Register for the Finnish cohort. Genetic information (apolipoprotein E allele) was available
for US cohort participants.

Author Manuscript

2.3 Statistical Analyses
Baseline characteristics were compared using descriptive statistics (mean, standard deviation
[SD], and range for continuous variables, and proportions for categorical variables). We used
the t test (or the Mann–Whitney test if normality assumptions were not met) to determine
statistical association with continuous variables, and the chi-square statistic to document the
statistical association with categorical variables. Prevalence of psychotropic medication use
by sex, overall, and for each of the different medication classes included in this category was
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evaluated for both cohorts. We also investigated whether age (<8 0 and ≥80 years), in
addition to sex, influenced our results.
We used unconditional logistic regression to estimate the association between sex and
psychotropic medication use. Two different multivariable models were developed for each
cohort to address confounding and to determine the adjusted estimates for odds ratio (aOR)
and the 95% CI. The first model included baseline characteristics available from both
countries (Table 1). The second model added country-specific information to those included
in the first model (Table 1 plus country-specific information from Table 2). All analyses
were conducted at the level of statistical significance of 0.05 using SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA) [41].

3 Results
Author Manuscript
Author Manuscript

The US cohort included 502 (45.68%) men and 597 (54.32%) women with AD, whereas the
Finnish cohort included 22,961 (34.24%) men and 44,088 (65.75%) women with AD. Table
1 shows the distribution of baseline characteristics by sex for the information available from
both cohorts. Additional country-specific baseline characteristics are included in Table 2.
Mean (SD) age for participants at the index date was 80.2 (7.43) for the US cohort and 80.6
(6.1) for the Finnish cohort. Men had a statistically significantly higher prevalence of
cardiovascular disease and diabetes (both countries), as well as stroke and epilepsy
(Finland); there were no sex differences for stroke and seizure history for US cohort
participants. When comparing the number of medications used, in the US, the prevalence of
using five or more medications was higher in men than in women (Table 1). In addition, men
in the US cohort were more likely to report the use of cognitive enhancers than women
(Table 1). When comparing psychotropic medication use by sex, women were more likely to
use psychotropic medications than men in both the US (46.2% [95% CI 42.2–50.3] vs.
33.1% [95% CI 28.9–37.4], p < 0.001) and Finland (45.3% [95% CI 44.8–45.8] vs. 36.1%
[95% CI 35.5–36.7], p < 0.001) (Table 1; Fig. 1). In relation to medication classes, the sex
difference was observed in both countries for antidepressants and anxiolytics, while sex was
associated with antipsychotic use in Finland only. When evaluating sex differences by age,
the pattern of use when comparing men and women remained the same for the two age
groups investigated (Fig. 2).
Of the behavioral symptoms evaluated from the NACC cohort, depression/ dysphoria was
most commonly reported by women (Table 2). No sex differences were observed between
men and women concerning other behavioral symptoms.

Author Manuscript

The results of the logistic regression analysis are presented in Table 3. Specifically, when
comparing women with men in the US cohort, the unadjusted odds ratio was 1.74 (95% CI
1.36–2.23), while the aOR was 2.08 (95% CI 1.59–2.71) in the limited data model, and 2.29
(95% CI 1.56–3.37) in the extended data model. The estimates from the Finnish data were
odds ratio = 1.47 (95% CI 1.42–1.52) in the unadjusted analysis and odds ratio = 1.39 (95%
CI 1.34–1.44) and odds ratio = 1.38 (95% CI 1.33–1.43) for the limited data model and the
extended data model, respectively. Similarly, in both countries, women were more likely to
use antidepressants or anxiolytics as compared with men, in both unadjusted and adjusted
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analyses. However, when looking at antipsychotic use, there was not a statistically
significant difference between women and men in the US cohort (Table 3). However, women
were more likely than men to report using antipsychotics in the Finnish cohort (Table 3).

4 Discussion

Author Manuscript

To our knowledge, this is the first study to explicitly investigate psychotropic medication use
according to sex in older adults with AD. We found that psychotropic medication use was
more common among older women than older men with AD in both the US (46 vs. 33%)
and Finland (45 vs. 36%). After adjusting for covariates, older women with AD were two
times more likely to receive psychotropic medications in the US cohort (aOR = 2.06; 95%
CI 1.58–2.70) and 1.4 times more likely (aOR = 1.38; 95% CI 1.33–1.43) in the Finnish
cohort, compared with older men. Despite differences in medication data collection
approaches across study cohorts (i.e., self-reported in the US vs. prescription registry data in
Finland), it is important to note that sex differences were apparent in both cohorts. Selfreported data are subject to bias and may have resulted in underreporting. However,
considering that the medication inventory in the US cohort was conducted using the brownbag approach, the potential misclassification of medication use by sex is likely nondifferential and thus probably underestimating the real sex difference. Although it was not
the primary focus of our article, it is worth noting that, in the US cohort, polypharmacy (five
or more medications) was more common among men than women, and men were more
likely to use cognitive enhancers than women. The reason for sex differences in cognitive
enhancers use should be further investigated in future studies.

Author Manuscript
Author Manuscript

The findings of our study are similar to recent studies comparing the use of cognitive
enhancers and psychotropic medications in women and men [1, 13, 42]. In a study
evaluating the prevalence of psychotropic medications use across different settings by
Medicare beneficiaries in the US, sex was an important factor associated with use [1].
Similarly, in a European study, women with dementia were more likely to use antipsychotics
than men [13]. A study using the National Health and Nutrition Examination Survey in the
US found that for all race categories, older women were more likely to report psychotropic
medication use than men [42]. In a recent study of community-dwelling older adults living
in Canada, older women were at 16% higher odds of receiving potentially inappropriate
medications, measured using 2015 Beers Criteria than older men [43]. These differences
were mostly the result of older women using psychotropic medications including
antidepressants and benzodiazepines. Older women are more likely like to have more comorbidities than men; therefore, this may in part explain differences in psychotropic
medication use. Moreover, the importance of considering personality traits as a potential
factor influencing psychotropic medication use has been also highlighted [44]. Future
studies investigating the role of sex in psychotropic prescribing patterns should account for
personality traits.
In our study, in the US cohort, psychotropic medication use consisted mainly of
antidepressant use, whereas antipsychotics and anxiolytics were less commonly used among
both men and women. In Finland, anxiolytics were the most frequently used psychotropic
medication among men, while antidepressants and anxiolytics were the most commonly
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used classes among women (Fig. 1). The prevalence of behavioral symptoms might explain
the observed difference between men and women. Previous studies have reported that
women experience behavioral symptoms, especially depressive symptoms, more frequently
than men [14, 45, 46]. We compared the prevalence of behavioral symptoms in the US
cohort and only depression and dysphoria were more frequently reported by women. We
also adjusted our regression model for behavioral symptoms in the US cohort and the
association between female sex and psychotropic medication use persisted. Antipsychotic
use was significantly more frequent in the Finnish cohort than in the US cohort. This
discrepancy might be related to AD disease severity or may reflect national treatment
practices and restricted use of antipsychotics in the US. Previous research evaluating
antipsychotic use in US veterans with dementia living in the community showed that 14–
15% of veterans had outpatient prescriptions for an antipsychotic [47]. In our US cohort,
95% of the participants had questionable or mild impairment (CDR global = 0.5 or 1), and a
small proportion had behavioral symptoms, which can explain the low prevalence of
antipsychotics. Furthermore, when looking at use by level of impairment, prevalence
increased from 1.17% for a CDR global score of 0.5–3.6% for CDR of 1, and to 34.62% for
a CDR of 2 or 3. In Finland, clinical care guidelines recommend antipsychotics and
anxiolytics only for short-term use and if non-pharmacological options are not effective [30].
However for the Finnish cohort, we did not have information on disease severity at the time
we measured antipsychotic use and we could not evaluate if the same pattern would be
identified in the US cohort. Both cohorts included persons newly diagnosed with AD, and
the mean age was similar.
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Importantly, there is a need for more research to elucidate the role of sex and its impact on
clinical outcomes among older people with and without dementia. Recent findings on the
association between antipsychotics and mood stabilizers and impairment on activities of
daily living in older women suggest sex differences in response to psychotropic medication
among older people with dementia living in NH [48]. In addition, it would be important to
investigate whether the observed sex differences in the use of psychotropic medications are
consistent over time.
4.1 Strengths and Limitations
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4.1.1 US Cohort—An important strength of the NACC data comes from the use of
validated instruments and standardized testing to collect patient-reported information and to
conduct in-depth cognitive evaluations in all study participants. One of the limitations in
using these data stems from the collection of data at enrollment and yearly after. Our
approach of defining the index date as the date a participant was first identified with AD
during follow-up in the cohort does not necessarily coincide with the time she/he was first
diagnosed with AD. In addition, given that medication use asked about current medications
taken by the participant (i.e., within 14 days of the visit), we could not ascertain
psychotropic medication exposure (and other medications) accurately. Participants may have
been misclassified as non-users in the situation in which they started and stopped treatment
between two consecutive study visits. Last, considering the recruitment strategies for the
NACC, participants enrolled in this cohort were not necessarily a representative random
sample for the entire US population of patients with or without cognitive impairment.
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Participants in the NACC cohort, and therefore in our study, were generally more educated,
had higher incomes, and were more likely to receive care in academic hospitals and clinics.
Thus, careful consideration is needed when attempting to generalize our findings to all older
adults with AD living in the US.
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4.1.2 Finnish Cohort—The MEDALZ cohort included all community-dwelling people
with clinically verified AD diagnosis in Finland. The strengths of these nationwide data
result from the inclusion of all socioeconomic classes and the fact that medication use is
assessed from registers, thus limiting recall bias or under-reporting. Limitations of the
MEDALZ data relate to limitations of registers used in data collection. Register-based data
do not include clinical information on behavioral symptoms and other indications for
psychotropic medication use. Furthermore, we could not assess MMSE or the severity of
AD, although all persons had a similar time period since AD diagnosis. However, possible
delays or sex differences in the diagnostic process could not be studied. While dispensing
data are considered a more accurate estimate of medication exposure than other sources of
prescribing data, they may not reflect the actual medication use.

5 Conclusion
We found that older women with AD are more likely to report psychotropic medication use
than older men in both countries. These findings may suggest that approaches to mitigate
psychotropic medication use among older people with dementia should consider different
prescribing habits observed in women vs. men. Further research is needed to elucidate
underlying risk factors for the differences in psychotropic medication use in women and men
with AD.

Author Manuscript
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Key Points
Older women with dementia were more likely to use
psychotropic medications than older men in the US (46 vs.
33%) and Finland (45 vs. 36%).
The difference between women and men with regard to
psychotropic medication use persisted even after accounting
for behavioral symptoms and other important confounders.
Our results suggest that sex needs to be taken into
consideration when prescribing to older people with
dementia.
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Fig. 1. Exposure to psychotropic medications according to sex in the US and Finnish cohorts
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Fig. 2. Exposure to psychotropic medications according to sex and age in the US and Finnish
cohorts
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110 (22.4)
269 (54.7)
104 (21.1)
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10 and more
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151 (30.1)
297 (59.2)

Memantine

Cholinesterase inhibitors

For the Finnish cohort, table includes N (%) with 95% CI for %

a

AD Alzheimer's disease, CI confidence interval, SD standard deviation

324 (64.5)

Any approved drugs for AD treatment

Cognitive enhancers, N (%)

9 (1.8)

1–4

288 (48.2)

131 (21.9)

312 (52.3)

127 (21.6)

267 (45.5)

175 (29.8)

18 (3.1)

0, 21

0

Number of medication categories, N (%)

Minimum, maximum

Mean (SD)

62 (10.4)

13 (2.2)

0, 20

74 (14.7)

Diabetes mellitus

6.6 (3.79)

11 (2.2)

Seizures (US cohort)/epilepsy (Finnish cohort)

38 (6.4)

411 (68.8)

65, 104

80.4 (8.02)

7 (3.59)

34 (6.8)

Stroke

Number of medications, N (%)

382 (76.1)

Cardiovascular disease

Co-morbidities, N (%)

79.8 (6.64)

Mean (SD)

Age at diagnosis (years)

<0.001

0.007

<0.001

0.008

0.128

0.029

0.988

0.786

0.008

0.175

13,341 (58.1; 57.5–58.7)

3280 (14.3; 13.8–14.7)

15,973 (69.6; 69.0–70.2)

2824 (12.3; 11.9–12.7)

10,493 (45.7; 45.1–46.3)

8809 (38.4; 37.7–39.0)

835 (3.6; 3.4–3.9)

0, 23

5.5 (3.3)

3764 (16.4; 15.9–16.9)

603 (2.6; 2.4–2.8)

3050 (13.3; 12.9–13.7)

12,481 (54.4; 53.7–55.0)

65, 101

79.5 (6.0)

Male (N = 22,961)

Male (N = 502)

p value

Finnish cohorta

US cohort
Female (N = 597)

Author Manuscript

Baseline characteristics

Author Manuscript
Table 1

24,850 (56.4; 55.9–56.8)

5777 (13.1; 12.8–13.4)

29,425 (66.7; 66.3–67.2)

6103 (13.8; 13.5–14.2)

20,872 (47.3; 46.9–47.8)

15,759 (35.7; 35.3–36.2)

1354 (3.1; 2.9–3.2)

0, 23

5.8 (3.4)

5536 (12.6; 12.3–12.9)

809 (1.8; 1.7–2.0)

3958 (9.0; 8.7–9.3)

22,601 (51.3; 50.1–51.7)

65, 103

81.2 (6.1)

Female (N = 44,088)

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

p value
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Table 2

Cohort-specific characteristics at the index date

Author Manuscript

Baseline characteristicsa

Male, N (%)

Female, N (%)b

White

446 (88.8)

491 (82.2)

Black

34 (6.8)

65 (10.9)

Other

22 (4.4)

41 (6.9)

High school or less

111 (22.21)

203 (34.0)

College

189 (37.95)

244 (40.87)

Graduate

202 (40.24)

150 (25.13)

Lives alone

49 (9.8)

214 (35.8)

Lives with spouse or partner

408 (81.3)

256 (42.9)

Other living arrangements

45 (9.0)

127 (21.3)

Single family residence

439 (87.5)

485 (81.2)

Retirement community

38 (7.6)

55 (9.2)

Assisted livinga

19 (3.8)

47 (7.9)

Other

6 (1.2)

10 (1.7)

p value

US cohort
Race

0.032

Education

<0.001

Living situation

<0.001

Author Manuscript

Type of residence

0.017

Level of independence

0.651

Author Manuscript

Able to live independently

184 (36.7)

199 (33.3)

Requires some assistance with complex activities

247 (49.2)

297 (49.7)

Requires some assistance with basic activities

60 (12.0)

88 (14.7)

Completely dependent

11 (2.2)

13 (2.2)

Mean (SD)

25.8 (3.63)

24.6 (4.72)

Q1, median, Q3

23, 25, 28

21, 24, 27

BMI

<0.001

BMI categories

<0.001

Obese

64 (14.4)

68 (13.6)

Global clinical dementia rating

0.776

No impairment

0 (0)

0 (0)

Questionable impairment

272 (54.2)

327 (54.8)

Mild impairment

207 (41.2)

237 (39.7)

Moderate/severe impairment

23 (4.6)

33 (5.5)

Normal

112 (23.0)

119 (21.3)

Mild

277 (57.0)

348 (62.4)

Moderate

81 (16.7)

72 (12.9)

Severe

2 (0.4)

3 (0.5)

Unknown

14 (2.9)

16 (2.9)

MMSE category

0.232

Author Manuscript
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Baseline characteristicsa

Male, N (%)

Female, N (%)b

Delusions

36 (7.4)

50 (8.6)

0.481

Hallucinations

11 (2.3)

21 (3.6)

0.199

Agitation or aggression

137 (28.3)

158 (27.2)

0.693

Depression or dysphoria

157 (32.4)

231 (39.8)

0.013

Anxiety

157 (32.4)

178 (30.7)

0.541

p value

Author Manuscript

Behavioral symptoms

Geriatric Depression Scale score categories

0.616

0–4

405 (84.2)

455 (81.1)

5–9

59 (12.3)

84 (15.0)

10–15

9 (1.9)

12 (2.1)

Unknown

8 (1.7)

10 (1.8)

Depression within the past 2 years

178 (35.5)

279 (46.7)

Psychiatric disorders

29 (5.8)

53 (8.9)

0.051

Transient ischemic attack

33 (6.6)

44 (7.4)

0.606

Incontinence: urinary

84 (16.7)

150 (25.1)

Co-morbidities

Author Manuscript

Apolipoprotein e4 alleles

<0.001

<0.001
0.119

No e4 allele

196 (39.0)

214 (35.8)

Any copy of e4 allele

225 (44.8)

258 (43.2)

Finnish cohort
Occupational socioeconomic position

<0.001

Author Manuscript

Office worker

714 (3.1; 2.9–3.3)

4954 (11.2; 11.0–11.5)

Farming/forestry

5195 (22.6; 22.1–23.2)

7748 (17.6; 17.2 –17.9)

Sales/industry/cleaning

10,528 (45.9; 45.2–46.5)

18,228 (41.3; 40.9–41.8)

Unknown

245 (1.1; 0.9–1.2)

5318 (12.1; 11.8–12.4)

Did not respond

159 (0.7; 0.6–0.8)

353 (0.8; 0.7–0.9)

Asthma/COPD

2077 (9.1; 8.7–9.4)

3908 (8.9; 8.6–9.1)

0.434

Rheumatoid arthritis

750 (3.3; 3.0–3.5)

2319 (5.3; 5.1–5.5)

<0.001

History of hip fracture

764 (3.3; 3.1–3.6)

3351 (7.6; 7.4–7.9)

<0.001

Hospital-treated depression

519 (2.3; 2.1–2.5)

1700 (3.9; 3.7–4.1)

Co-morbidities

BMI body mass index, CI confidence interval, COPD chronic obstructive pulmonary disorder, MMSE Mini-Mental State Examination, SD
standard deviation
a

Columns display N (%), unless otherwise specified

b

For the Finnish cohort, table includes N (%) with 95% CI for %
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Table 3

Psychotropic medication use in women as compared with men

Author Manuscript

Country

Unadjusted OR (95% CI)

Adjusted OR (95% CI)
Limited dataa

Adjusted OR (95% CI)
Extended datab

Any psychotropic medication
use

US

1.74 (1.36–2.23)

2.08 (1.59–2.71)

2.29 (1.56–3.37)

Finland

1.47 (1.42–1.52)

1.39 (1.34–1.44)

1.34 (1.29–1.39)

Antidepressant use

US

1.51 (1.18–1.93)

1.76 (1.34–2.3)

Finland

1.58 (1.52–1.65)

1.52 (1.46–1.59)

1.48 (1.41–1.55)

Antipsychotic use

US

0.85 (0.48–1.52)

0.79 (0.37–1.71)

Finland

1.17 (1.12–1.23)

1.09 (1.04–1.15)

1.05 (1.01–1.11)

Anxiolytic use

US

1.99 (1.31–3.05)

2.43 (1.49–3.98)

Finland

1.31 (1.26–1.36)

1.18 (1.13–1.23)

1.14 (1.09–1.19)

Author Manuscript

CI confidence interval, OR odds ratio
a

Model adjusted for variables available for both cohorts (Table 1)

b

Model adjusted for all variables available from that cohort (Tables 1, 2)

Author Manuscript
Author Manuscript
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2.16 (1.44–3.25)

0.61 (0.2–1.82)

2.16 (1.83–3.96)

